Juntuo Biopharma

Juntuo Biopharma (君拓生物) is a joint venture between Shenzhen-based microbiome drug developer Unknown君生物 (Unknown Biotech) and Beijing Kotek Biotechnology (北京科拓恒通生物技术股份有限公司), per a 2022 5Y Capital piece . Its notable asset is the KEX02 live biotherapeutic product (LBP) pipeline, which that August became one of the first China-origin microbial live drug candidates to receive FDA investigational new drug (IND) clearance for clinical trials, specifically in combination with a PD-1 inhibitor for non-small cell lung cancer . The bundle does not contain more recent updates on its pipeline progress or corporate status.